Saltar al contenido
Merck

909637

Sigma-Aldrich

NanoFabTx PLGA-nano

for synthesis of 100 and 200 nm particles

Sinónimos:

NanoFabTx, NanoFabTx reagent kit, PLGA nanoformulation kit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12162002
UNSPSC Code:
12161503
NACRES:
NC.25

description

PLGA nanoparticle screening kit for synthesis of 100 and 200 nm particles

Quality Level

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PLGA-nano reagent kit is a nanoformulation kit designed for the synthesis of specifically sized, drug-encapsulating poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The NanoFabTx PLGA-nano reagent kit provides reagents (PLGA and stabilizer) and protocols to synthesize polymeric nanoparticles 75 to 200 nm in size. One protocol describes how to use the kit with standard glassware using a nanoprecipitation or solvent-displacement method. The second protocol describes how to use the kit with the NanoFabTx Microfluidic - nano device kit (Cat.No. 911593) for the fabrication of nanoparticles using microfluidic methods.

Application

With NanoFabTx PLGA-nano reagent kit, users can simplify their methods for PLGA nanoparticle synthesis and their drug loading experiments. Our protocols describe how to tune the synthetic parameters to achieve monodisperse nanoparticles 75 nm in size, 200 nm in size, or any size in between. As a result, the kit enables users to synthesize and test different particle sizes and identify the ideal size and drug loading of PLGA nanocarriers for their research application. The resulting particles are biocompatible and biodegradable and can be further modified to target specific tissues or to ensure slow and sustained drug release. PLGA is a biocompatible and biodegradable polymer that is approved by the FDA for biomedical and pharmaceutical applications and that is used widely in drug delivery systems for sustained release of many different types of therapeutic molecules. PLGA-based nanocarriers can be used to encapsulate both hydrophobic drugs like curcumin and lipophilic drugs like docetaxel. PLGA nanocarriers synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery. Polymeric nanoparticles are useful for intravenous or systemic delivery of drug molecules. For example, polymeric nanocarriers improve drug dissolution and solubility of hydrophobic and lipophilic drugs. In addition, the small size of polymeric nanocarriers make them much more likely than larger microparticles to bypass the reticuloendothelial system and complement system, usually leading to longer circulation half-lives. In addition, nanoparticles can pass through the blood-brain barrier, through tumor vasculature, and can enter cells via pinocytosis.

Features and Benefits

  • Step-by-step protocols developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible nanoparticles
  • Choose from standard glassware-based nanoprecipitation or microfluidic-based protocols
  • Optimized to make nanoparticles 75-200 nm nanoprecipitation or microfluidics with low polydispersity
  • Based on non-toxic, biodegradable polymers

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Gaurav Kumar et al.
Critical reviews in therapeutic drug carrier systems, 29(2), 149-182 (2012-04-06)
Drug-loaded polylactide-co-glycolide (PLGA) nanoparticles have been extensively studied and have a practical impact on drug delivery. Many PLGA-based nanoformulations have reached different stages of preclinical development; however, they present distinct challenges for researchers. This review discusses some of the challenges
Francesca Ungaro et al.
The Journal of pharmacy and pharmacology, 64(9), 1217-1235 (2012-08-14)
The aim of this review is to summarize the current state-of-the-art in poly(lactic-co-glycolic acid) (PLGA) carriers for inhalation. It presents the rational of use, the potential and the recent advances in developing PLGA microparticles and nanoparticles for pulmonary delivery. The
Anil Mahapatro et al.
Journal of nanobiotechnology, 9, 55-55 (2011-11-30)
Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a viable carrier for site specific delivery of vaccines, genes, drugs and other biomolecules in the body. They offer enhanced biocompatibility, superior drug/vaccine encapsulation, and convenient release
Amit K Jain et al.
Critical reviews in therapeutic drug carrier systems, 28(1), 1-45 (2011-03-15)
Nanocarriers formulated with the US Food and Drug Administration-approved biocompatible and biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) are being widely explored for the controlled delivery of therapeutic drugs, proteins, peptides, oligonucleotides, and genes. Surface functionalization of PLGA nanoparticles has paved the
L Martin-Banderas et al.
Mini reviews in medicinal chemistry, 13(1), 58-69 (2012-09-15)
This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either

Artículos

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico